Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
10 févr. 2022 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
10 janv. 2022 08h00 HE
|
Solid Biosciences Inc.
- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced...
Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources
04 janv. 2022 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
03 nov. 2021 07h05 HE
|
Solid Biosciences Inc.
- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene...
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
02 nov. 2021 07h30 HE
|
Solid Biosciences Inc.; The Pathway Development Consortium; REGENXBIO Inc.
- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development...
Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
21 oct. 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
29 sept. 2021 07h00 HE
|
Solid Biosciences Inc.
- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post...
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
23 sept. 2021 06h00 HE
|
Solid Biosciences Inc.
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital...
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
20 sept. 2021 16h05 HE
|
Solid Biosciences Inc.
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021...